2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 2026
31.7.2026 13:42:00 CEST | Business Wire | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/

Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire)
Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion.
Through continued operational integration, the adoption of more AI tools and ongoing cost optimization, the Group strengthened its operational performance. This helped Group revenue rise to AED 21.9 billion, while the blended gross profit margin remained stable at 29% to sustain long-term profitability across the core portfolio.
Samia Bouazza, CEO of 2PointZero said: “The first half of 2026 demonstrates the strength of the platform we have been building over several years. We delivered revenue of AED 21.9 billion, representing a 114% increase on a pro forma like-for-like basis, and Group Net Profit of AED 7.7 billion, comprising AED 2.2 billion from our operating businesses alongside one-off gains from our investment portfolio, including SpaceX, Anthropic, and other investment gains, while continuing to strengthen the quality of our portfolio and the resilience of our balance sheet.
“Beyond the financial results, this period marked an important step in the evolution of 2PointZero. We completed the successful monetization of our TAQA investment, demonstrating our ability to divest some assets at the right time, expanded into North American energy infrastructure through the acquisition of Traverse Midstream Partners, representing ePointZero's largest investment in energy infrastructure to date. Each transaction reflects our disciplined approach to capital allocation and our commitment to building globally relevant businesses geared towards solving global bottlenecks.
“Our recognition by TIME as one of the World’s Growth Leaders reflects not only our pace of growth, but also the stability, operational discipline, and long-term mindset that define our organisation.
“Supported by a strong group cash position of AED 13.7 billion, we remain well positioned to invest through market cycles. In today's environment, sitting on cash is a strategic advantage.
“As we enter the second half of the year, we continue to strengthen the platform for long-term growth. Nearly 10% of our workforce consists of AI co-workers, embedded across the Group to improve productivity, accelerate decision-making, and strengthen operational performance. Together with our disciplined capital allocation and strong financial position, this gives us confidence in our ability to create long-term shareholder value.”
The Group’s financial foundation remains firm, supported by a group cash position of AED 13.7 billion and a debt-to-equity ratio of 0.32. This strong capital structure provides the flexibility to manage risks, allocate resources efficiently, and fund high-return investment opportunities globally as 2PointZero’s long-term strategy continues to deliver results across core verticals.
Group Highlights
In June 2026, 2PointZero Group completed the sale of its full 7.29% stake in TAQA to Abu Dhabi Power, further strengthening its financial position and enhancing flexibility to pursue attractive opportunities across various core sectors.
More recently, 2PointZero expanded its energy infrastructure footprint through its subsidiary ePointZero, which successfully completed the acquisition of a 100% stake in Traverse Midstream Partners for USD 2.25 billion in an all-cash transaction.
Furthering its tactical reach into high-potential consumer segments, 2PointZero participated in the Series G funding round for WHOOP, a pioneer in the global health, introducing a category-defining asset to the Group’s Wellness portfolio.
In a decisive move to launch its sixth dedicated consumer vertical, The Group finalised the acquisition of a 60.8% controlling interest in Italy’s ISEM Packaging Group for AED 704 million, strengthening 2PointZero’s exposure to high-growth end markets.
International Resources Holding (IRH) and Adani Enterprises have agreed to form a 50:50 joint venture to develop an US$11.5 billion aluminium project in India. This move reinforces IRH’s strategy of connecting capital, infrastructure, and trade to create long-term value.
In another key development, FAB Securities initiated coverage on 2PointZero Group with a BUY rating and a target price of AED 3.30 per share, highlighting the Group’s diversified exposure, AI-enabled operating model, disciplined capital allocation and strong financial performance.
Recognising its strong financial performance, 2PointZero was ranked 36th on TIME’s inaugural list of World’s Growth Leaders for 2026, highlighting its robust business growth, exceptional market performance, and long-term financial stability.
In July 2026, the Abu Dhabi Securities Exchange expanded its derivatives market by listing 2PointZero Group as one of six new single-stock futures, broadening international investor participation, and raising the company’s profile on global trading platforms.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20260731538982/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom